Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A. Judson I, et al. Cancer Chemother Pharmacol. 2005 Apr;55(4):379-386. doi: 10.1007/s00280-004-0876-0. Epub 2004 Dec 9. Cancer Chemother Pharmacol. 2005. PMID: 15592836
Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D, Judson IR. Verweij J, et al. Among authors: judson ir. J Clin Oncol. 2000 May;18(10):2081-6. doi: 10.1200/JCO.2000.18.10.2081. J Clin Oncol. 2000. PMID: 10811673 Clinical Trial.
A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
O'Donnell A, Punt CJ, Judson I, Van Maanen L, Suttle AB, Ertel P, Beale P. O'Donnell A, et al. Among authors: judson i. Cancer Chemother Pharmacol. 2003 Jan;51(1):58-66. doi: 10.1007/s00280-002-0536-1. Epub 2002 Nov 20. Cancer Chemother Pharmacol. 2003. PMID: 12497207
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. van Oosterom AT, et al. Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7. doi: 10.1016/s0959-8049(02)80608-6. Eur J Cancer. 2002. PMID: 12528778 Clinical Trial.
Sarcoma.
Scurr M, Judson I. Scurr M, et al. Among authors: judson i. Cancer Chemother Biol Response Modif. 2003;21:637-53. doi: 10.1016/s0921-4410(03)21030-9. Cancer Chemother Biol Response Modif. 2003. PMID: 15338767 Review. No abstract available.
The development and application of imatinib.
Jones RL, Judson IR. Jones RL, et al. Expert Opin Drug Saf. 2005 Mar;4(2):183-91. doi: 10.1517/14740338.4.2.183. Expert Opin Drug Saf. 2005. PMID: 15794712 Review.
393 results